Testimonials
The election is over, and with it also comes the end (for now) of the seemingly endless text messages, mail, dinnertime phone calls, and TV and social media ads. But there are many questions as to what comes next and not a lot of answers just yet. Listen to "Unscripted" The AMCP Podcast, for updates from the new Trump administration and Congress's health policy agenda from AMCP.
AMCP 2024 AAO Report
AMCP's feature annual report explores how professionals in managed care pharmacy work diligently to facilitate appropriate access to prescription treatments while remaining mindful of rising costs. It discusses key areas of focus such as pharmacy benefit design, formulary management, clinical programs, quality, safety and promoting affordability of medicines.
AMCP eModel is the ultimate tool for communication of health economic models and value evidence. Find out more about this tech partnership and this health economic modeling platform to support the exchange of clinical and economic information between manufacturers and payers.
AMCP partners with FormularyDecisions to enhance information sharing and formulary decision-making by creating a platform for current, credible, and compliant information exchange between life science companies and active, qualified healthcare decision-makers.
Featured
-
Health Information Technology Resources
-
Digital Therapeutics Resources
-
Health Disparities Resources
-
Value-Based Contracts Resources
Meetings Proceedings & Findings
View More
Latest News & Resources
This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.
Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.
Slide deck from the AMCP Partnership Forum "Addressing Evidence Gaps in the Expedited Review Process: Payer Perspectives."
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
Proceedings from the AMCP Partnership Forum on High-Investment Medications.
Presentation from the AMCP Partnership Forum: High-Investment Medications.
AMCP supports the use of preferred pharmacy networks as a way of providing additional options to incentivize higher quality care and improve cost-effectiveness.
A webinar that reviews several approved and numerous investigational cell and gene therapies, and discusses potential strategies for cell and gene therapy companies to consider that may help mitigate reimbursement challenges.
Sponsored webinar that discusses the current status of Hepatitis B in the U.S., challenges in Hepatitis B prevention, and an overview of VBI Vaccines’ newly-approved HBV Vaccine.
Expert Perspectives: The Intersection of Technology and Patient Centricity in Chronic Kidney Disease
This sponsored webinar will provide an opportunity to distill information and be a forum on the topic of Population Health in Chronic Kidney Disease (CKD).
These disease state webinars are sponsored, developed and presented by PRIME.
Sponsored webinar that discussed how health care providers (HCPs) apply current evidence-based IBS treatment guideline recommendations while simultaneously navigating managed care criteria that influences the care of the patients with IBS-C.
